Markable coagulopathy in the patient with severe COVID-19
https://doi.org/10.21886/2712-8156-2022-3-3-91-96
Abstract
The variative coagulation abnormalities with thrombotic and microvascular complications are distinguishing feature of the severe new coronavirus infection (COVID-19) pathogenesis. Abnormal coagulopathy is directly related to the risk of death in COVID-19 patients. In many patients with COVID-19, hemostasis disorders have been observed, which increase the risk of developing DIC (disseminated intravascular coagulation), thrombotic microangiopathy or antiphospholipid syndrome as a result of the pathogenetic factors combination: inflammatory response, endothelial dysfunction, increased platelet consumption, microvascular thrombosis. The mechanism of coagulopathy associated with COVID is still being found, COVID-associated coagulopathy exemplifies the potentiating multi-factor interactions between the immune system and the coagulation. We’re reporting a fatal case of 51-year-old male with COVID-19, complicated by severe acute respiratory syndrome (SARS) and severe thrombocytopenia, markedly enhanced fibrinolytic activity with skin-hemorrhagic syndrome, thrombotic complication (myocardial infarction), probably related to the DIC. This case demonstrates the need more basic and clinical research is warranted to further our understanding of the role of coagulation disorders mechanism in COVID-19 to prevent severe outcomes and mortality.
About the Authors
A. A. Roshchina
Federal State Budgetary Educational Institution of Higher Education «Saratov State Medical University n. a. V. I. Razumovsky» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Anna A. Roshchina, PhD, Associate Professor of the of Hospital Therapy Department of the Medical Faculty
Saratov
M. I. Yupatova
Federal State Budgetary Educational Institution of Higher Education «Saratov State Medical University n. a. V. I. Razumovsky» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Maria I. Yupatova, Resident of the Hospital Therapy Department of the Medical Faculty
Saratov
N. M. Nikitina
Federal State Budgetary Educational Institution of Higher Education «Saratov State Medical University n. a. V. I. Razumovsky» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Natalia M. Nikitina, Doctor of Medical Sciences, Professor of the of Hospital Therapy Department of the Medical Faculty
Saratov
References
1. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–116. DOI: 10.1016/j.coi.2021.07.003
2. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844– 847. DOI: 10.1111/jth.14768
3. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33. DOI: 10.1111/j.1365-2141.2009.07600.x
4. Hoechter DJ, Becker-Pennrich A, Langrehr J, Bruegel M, Zwissler B, Schaefer S, et al. Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients. Thromb Res. 2020;196:186– 192. DOI: 10.1016/j.thromres.2020.08.030
5. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681–686. DOI: 10.1016/S2213-2600(20)30243-5
6. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. DOI: 10.1056/NEJMoa2015432
7. Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost. 2020;120(8):1230–1232. DOI: 10.1055/s-0040-1712097
8. Berger JS, Kunichoff D, Adhikari S, Ahuja T, Amoroso N, Aphinyanaphongs Y, et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19. Arterioscler Thromb Vasc Biol. 2020;40(10):2539–2547. DOI: 10.1161/ATVBAHA.120.314872
9. Nugroho J, Wardhana A, Mulia EP, Maghfirah I, Rachmi DA, A’yun MQ, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221–231. DOI: 10.3233/CH-200978
10. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467–474. DOI: 10.1016/j.ijid.2020.05.055
11. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417– 1418. DOI: 10.1016/S0140-6736(20)30937-5
12. Baker CJ, Smith SA, Morrissey JH. Polyphosphate in thrombosis, hemostasis, and inflammation. Res Pract Thromb Haemost. 2018;3(1):18–25. DOI: 10.1002/rth2.12162
13. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38. DOI: 10.1056/NEJMc2007575
14. El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120978667. DOI:10.1177/1179544120978667
15. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021;88(1):15–27. DOI: 10.1159/000512007
16. Юпатов В.Д., Пономарева Е.Ю. COVID-19 ассоциированная коагулопатия: патогенетические особенности и практические аспекты диагностики и лечения (обзор). Саратовский научно-медицинский журнал. 2021;17(4):741–746. eLIBRARY ID: 48155719
17. Галстян Г.М. Коагулопатия при COVID-19. Пульмонология. 2020;30(5):645–657. DOI: 10.18093/0869-0189-2020-30-5-645-657
18. Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care. 2020;24(1):275. DOI: 10.1186/s13054-020-03025-y
19. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500. DOI: 10.1182/blood.2020006520
20. Mechineni A, Nanavati S, Solis RA, Ismail M. Dilemma of systemic anticoagulation: a COVID-19 patient with spontaneous chest wall hematoma. Chest. 2020;158(4):A409. DOI: 10.1016/j.chest.2020.08.400
21. Камкин Е.Г., Костенко Н.А., Каракулина Е.В., Авдеев С.Н., Адамян Л.В., Байбарина Е.Н. и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020). Министерство здравоохранения Российской Федерации. 2020. С. 165
22. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264. DOI: 10.1016/j.jacc.2018.08.1038
23. Liu S, Song C, Zhao Y, Guan C, Zhu C, et al. Impact of baseline thrombocytopenia on the long-term outcome of patients undergoing elective percutaneous coronary intervention: An analysis of 9,897 consecutive patients. Catheter Cardiovasc. Interv. 2019;93(1):764-771. DOI: 10.1002/ccd.28030
24. Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–589. DOI: 10.1038/s41584-020-0474-5
25. Rungjirajittranon T, Owattanapanich W. A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report. J Med Case Rep. 2019;13(1):25. DOI: 10.1186/s13256-018-1955-x.
Supplementary files
Review
For citations:
Roshchina A.A., Yupatova M.I., Nikitina N.M. Markable coagulopathy in the patient with severe COVID-19. South Russian Journal of Therapeutic Practice. 2022;3(3):97-107. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-3-91-96
Views:
1624
Email this article 